Ginseng Polysaccharides Inhibit Aspergillus sydowii-Driven Lung Adenocarcinoma via Modulating Gut Microbiota-Bile

Jinlian He1, Xiao Shu2, Hudan Pan2

  • 1Guangzhou National Laboratory, Guangzhou 510000, China.

Cancers
|October 16, 2025
PubMed
Abstract

Insights

Ginseng polysaccharides (GPs) combat Aspergillus sydowii-driven lung cancer by restoring gut bacteria and altering bile acids. This research highlights GPs as a potential therapy for fungal-related cancers.

Area of Science:

  • Oncology
  • Microbiology
  • Pharmacology

Background:

  • Lung adenocarcinoma (LUAD) is a leading global cancer killer, often driven by the oncogenic fungus Aspergillus sydowii (A. sydowii).
  • Intratumoral mycobiomes contribute to LUAD pathogenesis.
  • Ginseng polysaccharides (GPs) possess immunomodulatory and oncostatic properties, showing potential against fungal infections in LUAD.

Purpose of the Study:

  • To investigate the antitumor effects of Ginseng polysaccharides (GPs) against Aspergillus sydowii-induced lung adenocarcinoma (LUAD).
  • To explore the impact of GPs on gut microbiota and bile acid metabolism in LUAD models.

Main Methods:

  • Established subcutaneous and orthotopic LUAD murine models using Lewis lung carcinoma (LLC) cells.
  • Administered GPs (200 mg/kg/day) orally and infected models with A. sydowii.
  • Performed metagenomic and bile acid metabolomic profiling, analyzing Spearman correlations.

Main Results:

  • GPs significantly inhibited A. sydowii-induced tumor growth, reducing volume and weight in subcutaneous models and pathological nodules in orthotopic models.
  • Metagenomics revealed GPs restored gut homeostasis by increasing beneficial Lactobacillus/Muribaculum intestinale and decreasing pro-inflammatory Alistipes.
  • Metabolomics showed GPs reduced specific bile acids (3β-HDCA, CDCA-24G, 5-isoLCA), with network analysis confirming microbe-bile acid interactions.

Conclusions:

  • Ginseng polysaccharides demonstrate antitumor efficacy against A. sydowii-induced LUAD.
  • GPs modulate gut microbiota and bile acid metabolism to achieve these effects.
  • GPs represent a promising therapeutic strategy for mycobiome-influenced cancers, targeting both fungal infection and metabolic reprogramming.